Last10K.com

Zalicus Inc. (EPRS) SEC Filing 10-K Annual report for the fiscal year ending Monday, December 31, 2012

Epirus Biopharmaceuticals, Inc.

CIK: 1135906 Ticker: EPRS

ZALICUS

ZALICUS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR END 2012

Provides Key Goals for 2013

CAMBRIDGE, Mass. – March 6, 2013

– Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today reported financial results for the fourth quarter and year ended December 31, 2012.

“We are focused on advancing the development of our ion channel programs, including Z160, our first-in-class, oral N-type calcium channel blocker for the treatment of chronic neuropathic pain and Z944, a novel oral T-type calcium channel blocker,” commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “During 2012 we made a number of advances with our novel ion channel programs, including advancing Z160 into Phase 2a clinical development and Z944 into the clinic. We plan to build on this success in 2013 by generating proof-of-concept data for Z160 in multiple indications and continuing the clinical development of Z944.”

Fourth Quarter 2012 and Recent Accomplishments:

·      Z160. Advanced Z160, a first-in-class, oral, state dependent, selective N-type calcium channel (Cav 2.2) blocker into the second of two Phase 2a clinical trials for the potential treatment of chronic neuropathic pain, including lumbosacral radiculopathy which began in the third quarter of 2012 and postherpetic neuralgia which began in the fourth quarter of 2012. Top line data from both studies are expected to be available late in the second half of 2013.
 
·      Z944. Received a key U.S. patent issued in February 2013 providing broad patent coverage for Z944, a novel, oral, T-type calcium channel blocker, through April 2029. Z944 completed Phase 1 single and multiple ascending dose clinical studies in late 2012 and the Company plans to continue further clinical development with Z944 during 2013.
 
·      cHTS™. Generated approximately $7.3 million of revenue in 2012 from our combination High Throughput Screening (cHTS) collaborations.
 

2013 Zalicus Pipeline and Business Goals:

Zalicus has set the following goals for 2013, which include internal research and development programs, collaborations and financial goals:

·      Ion Channel Programs:
 
  o      Successfully advance Z160 through Phase 2a proof-of-concept clinical studies and report top-line data by year-end 2013
 
  o      Advance Z944 through further clinical development including completing one experimental medicine clinical study in 2013
 
  o      Nominate a sodium channel lead for further preclinical development in 2013
 
·      Continue to expand and diversify our cHTS services to generate surplus cash for the Company
 
·      Target year-end on-going financial strength with sufficient cash through 2014
 

245 First Street, Third Floor, Cambridge, MA 02142
Ph: 617 301 7000 Fax: 617 301 7010 www.zalicus.com

The following information was filed by Epirus Biopharmaceuticals, Inc. (EPRS) on Wednesday, March 6, 2013 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Epirus Biopharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Epirus Biopharmaceuticals, Inc..

Continue

Assess how Epirus Biopharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Epirus Biopharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2013 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Stockholders' Equity
Accrued Expenses
Accrued Expenses (details)
Accrued Expenses (tables)
Commitments
Commitments (details 1)
Commitments (details Textual)
Commitments (details)
Commitments (tables)
Common Stock
Common Stock (details)
Employee Benefit Plans
Employee Benefit Plans (details)
Income Taxes
Income Taxes (details 1)
Income Taxes (details 2)
Income Taxes (details 3)
Income Taxes (details Textual)
Income Taxes (details)
Income Taxes (tables)
Intangible Assets
Intangible Assets (details Textual)
Intangible Assets (details)
Intangible Assets (tables)
Merger With Neuromed Pharmaceuticals, Inc.
Merger With Neuromed Pharmaceuticals, Inc. (details)
Nature Of The Business
Nature Of The Business (details)
Net Loss Per Share
Net Loss Per Share (details)
Net Loss Per Share (tables)
Property And Equipment
Property And Equipment (details Textual)
Property And Equipment (details)
Property And Equipment (tables)
Quarterly Financial Information (unaudited)
Quarterly Financial Information (unaudited) (tables)
Quarterly Financial Information (unaudited) (details)
Research And Development Agreements
Research And Development Agreements (details)
Research Collaboration Agreement
Research Collaboration Agreement (details)
Restructuring
Restructuring (details Textual)
Restructuring (details)
Restructuring (tables)
Segment And Geographic Information
Segment And Geographic Information (details)
Short-term Investments
Short-term Investments (details 1)
Short-term Investments (details Textual)
Short-term Investments (details)
Short-term Investments (tables)
Stock Compensation Plans
Stock Compensation Plans (details 1)
Stock Compensation Plans (details 2)
Stock Compensation Plans (details 3)
Stock Compensation Plans (details Textual)
Stock Compensation Plans (details)
Stock Compensation Plans (tables)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (details Textual)
Summary Of Significant Accounting Policies (details)
Summary Of Significant Accounting Policies (policies)
Summary Of Significant Accounting Policies (tables)
Term Loan Payable
Term Loan Payable (details Textual)
Term Loan Payable (details)
Term Loan Payable (tables)
Ticker: EPRS
CIK: 1135906
Form Type: 10-K Annual Report
Accession Number: 0001193125-13-096030
Submitted to the SEC: Thu Mar 07 2013 4:16:56 PM EST
Accepted by the SEC: Thu Mar 07 2013
Period: Monday, December 31, 2012
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/eprs/0001193125-13-096030.htm